four phases of the estrous cycle. Interestingly, we find that the effects of fluoxetine on both 57 behavior and adult hippocampal neurogenesis are driven by mice specifically in the estrus or 58 diestrus phases of the estrous cycle. Taken together our data is the first to illustrate the impact of 59 fluoxetine on brain and behavior across all four stages of the murine estrous cycle. 60 61 Highlights: 62
these studies illustrate the influence of the estrous cycle on animal behavior, they were 81 predominately conducted in rats not mice. In comparing two mouse strains, Meziane and 82 colleagues (2007) observed that C57BL/6J females have less variation in anxiety-like behaviors 83 across the estrous cycle than BALB/cByJ females. However, commonly used negative valence 84 tests associated with anxiety-like behavior, such as elevated plus maze (EPM) and novelty 85 suppressed feeding (NSF), were not included in this study. Therefore, detailed behavioral 86 analyses across the mouse estrous cycle is still needed. 87
Variations in gonadal steroid hormone secretion patterns, as seen in cycling females, can 88 contribute to hippocampal structural and functional impairments, such as alterations in adult 89 neurogenesis (Tanapat et al., 2005; Barha et al., 2009 ) within the subgranular zone of the dentate 90 gyrus (DG) (Tanapat et al., 1999 of entries, distance traveled, and total time spent in the center were recorded, as 145 well as percent of distance traveled in the center defined as center distance 146 divided by total distance traveled (Supplemental Figure 1A) . To measure overall 147 motor activity total distance (cm) was quantified. 148
Novelty Suppressed Feeding (NSF) 149
After undergoing 18 hours of food deprivation within their home cage, mice were 150 placed in the corner of a testing apparatus (50x50x20 cm) filled with 151 approximately 2 cm of corncob bedding and a single pellet of food attached to a 152 white platform in the center of the box. The center of the box was illuminated at 153 1500 lux. The NSF test lasted 6 minutes, where the latency to eat (defined as the 154 mouse sitting on its haunches and biting the pellet with the use of forepaws) was 155 timed/recorded. If a mouse did not consume food during the NSF a latency of 156 360secs was recorded. Immediately afterwards, the mice were transferred to their 157 home cage to assess home cage feeding behavior for 5 minutes (Supplemental 158 Figure 1D -F). During this task latency to eat and amount of food consumed was 159 measured as a control for feeding behavior observed in the NSF task. Each mouse 160 was weighed before food deprivation and after home cage feeding to assess the Figure 1C ). Using Activity Monitor (Kinder Scientific, USA) software, total time 174 in the light and ambulatory distance in both compartments was analyzed. To 175 calculate percent distance traveled in the light, distance traveled in the light was 176 divided by total distance traveled (Supplemental Figure 1B) . 177
Elevated Plus Maze (EPM) 178
The EPM test consisted of a plus- 
Ki67 labeling for cell proliferation 206
The effects of FLX treatment on cell proliferation were assessed across 12 serial 207 sections of the hippocampus. Using mailers, slides were washed in 1% Triton X-208 100 PBS for 5 minutes before undergoing three PBS washes. Next, slides were 209 incubated in warm citrate buffer for 30 minutes and then washed times in PBS. 210
Slides were then transferred to an opaque moisture chamber (details) for the 211 blocking and overnight incubation step. Slides were blocked for 1 hour in 10% 212 normal goat serum (NGS) diluted in PBS before being incubated overnight at 4°C 213 in anti-rabbit ki67 (1:500; abCam, ab16667) diluted in 2% NGS PBS. Following 214 18 hours of incubation slides were washed 3 times in PBS before being incubated 215 at room temperature for 2 hours in CY-5 goat anti-rabbit (1:1000, Invitrogen, 216
Thermo Fisher Scientific, A10523) diluted in 2% NGS PBS. Next slides were 217 washed with PBS then counterstained with DAPI (1:15000) for 15 minutes. 218
Finally, slides were washed with PBS and cover slipped using the mounting 219 medium prolong diamond. Fluorescent images were taken using a EVOS FL Auto 220 2.0 microscope (Thermofisher Scientific) at 10x magnification, where ki67 + cells 221 overlayed with DAPI across the 12 sections of hippocampus were collected and 222 counted. 223
Doublecortin (DCX) labeling for maturation 224
12 serial hippocampal sections for doublecortin (DCX) were stained using the 225 primary antibody doublecortin anti-goat (1:500; Life technologies; 481200) and 226 secondary antibody CY-5 goat anti-rabbit (1:1000, Invitrogen, Thermo Fisher 227 Scientific, A10523). Fluorescent images were taken using using a EVOS FL Auto 228 
Statistical Analyses 235
To analyze both behavioral and molecular differences between treatment groups and 236 estrous cycle stages separate 2x4 analyses of variance (ANOVA) were conducted. Each 237 ANOVA was followed by subsequent Bonferroni post-hoc analyses to further assess 238 between and within group differences across the estrous cycle. Since we imposed a cutoff 239 time during the NSF, we ran a Kaplan Meier survival analysis (nonparametric test) that 240 permits censoring of these data points to analyze differences in feeding latencies. 241
Results 242

FLX and vehicle behavioral differences across estrous cycle 243
We treated a large cohort of adult C57BL/6J female mice (n= 41) with 18mg/kg FLX for 244 three weeks ( Figure 1A ) and then exposed these mice to the Open Field (OF) 1D), with a nonsignificant trend emerging in the metestrus phase (t(9) = 2.62, p = 0.052). We 258 found no significant effects of treatment or estrous phase nor interaction effect on behaviors 259 within the OF and LD tests (Supplemental Figure 1A-C) . 260
In the NSF, a Kaplan Meier survival analysis log rank test revealed that FLX 261 significantly reduces latency to feed, x 2 (1) = 8.37, p = 0.0038 ( Figure 1E, 1F) , as compared 262 to vehicle mice. Additionally, we observed that the estrus phase of the estrous cycle impacted 263 group differences in latency to feed, with FLX females in estrus having lower latencies to 264 feed than estrus vehicle females x 2 (1) = 6.9, p = 0.008. There was no treatment effect nor 265 estrous effect on home cage latency, amount of food consumed in home cage, or percent 266 weight change (Supplemental Figure 1D-F) . 267
Taken together, these data suggest that the effects of FLX on behavior are most 268 consistent across tests during the estrus stage. 269
Fluoxetine treatment and estrous cycle state impact adult neurogenesis 270
Several days following the FST, we perfused the mice and collected serial sections 271 through the DG. Next, we performed immunostaining to determine the effects of FLX on the 272 distinct stages of adult hippocampal neurogenesis across the different phases of the estrous 273 cycle. We first stained for the cell proliferation marker Ki67 and found that FLX-treatedmice had more Ki67 + cells than vehicle-treated mice F(1, 37) = 5.34, p = 0.026 (Figure 2A ). 275
We observed no estrous cycle effects nor interaction on number of Ki67 + cells (p's > 0.05). 276
We next performed immunostaining with the young neuron marker DCX, and observed 277 that FLX-treated mice showed more DCX + cells within the DG than vehicle-treated mice 278 F(1, 37) = 13.44, p < 0.001. We found a significant interaction effect between treatment and 279 estrous phase F(3, 37) = 4.57, p = 0.008. Planned post-hoc comparisons revealed that FLX-280 treated mice had more DCX + cells than vehicle mice within the estrus (t(9) = 3.95, p < 0.001) 281 and diestrus (t(11) = 3.29, p = 0.009; Figure 2B ) phases. Within the vehicle group, planned 282 comparisons revealed that proestrus females had significantly more DCX + cells than both 283 estrus (t(10) = 4.76, p = 0.001) and diestrus (t(11) = 3.71, p = 0.01) female mice ( Figure 3A) . 284
Additionally, metestrus vehicle-treated mice had significantly more DCX + cells than both 285 estrus (t(9) = 4.8, p < 0. Figure 3B ). Planned comparisons alsorevealed that metestrous vehicle-treated females had more mature neurons than estrus (t(9) = 298 4.94, p = 0.013) and diestrus (t(9) = 4.06, p = 0.04) vehicle-treated females ( Figure 3B) . 299
Within the FLX group, we observed no differences in expression of DCX + cell with tertiary 300 dendrites across the estrous cycle. 301
Lastly, we observed that FLX mice have a higher maturation index (F(1, 37) = 10.98, p = 302 0.002; Figure 2D ) than vehicle mice. We observed a significant interaction effect between 303 treatment group and estrous cycle phase (F(3, 37) = 3.23, p = 0.033), with FLX females 304 having a significantly higher maturation index than vehicle females in both the estrus, (t(9) = 305 3.07, p = 0.004) and diestrus (t(11) = 3.13, p = 0.003) phases ( Figure 2D ). Within both the 306 vehicle ( Figure 3C ) and FLX group we observed no differences in the maturation index 307 across the estrous cycle. Taken together, these data suggest that the effects of fluoxetine on 308 adult hippocampal neurogenesis are most pronounced during both the estrus and diestrus 309 stage. 310
Discussion 311
FLX and vehicle behavioral differences across estrous cycle 312
We used an array of negative valence behavioral tests to evaluate the impact of 313 antidepressant treatment on anxiety-like behaviors across the estrous cycle. Prior to 314 behavioral testing we tracked the females estrous cycle for two weeks to assess whether 315 females were cycling together within the same housing room. Although Meziane and 316 colleagues (2007) Diestrus FLX-treated females had lower immobility times in the FST than diestrus vehicle 325 females, but FLX was ineffective in the anxiety-related EPM and NSF tasks. Furthermore, 326 the behavioral effects of FLX were not significant in any of these tasks during metestrus and 327 proestrus. Recently, Sayin and colleagues (2014) observed that proestrus rats display less 328 anxiety-like behaviors than non-proestrus rats in the EPM, with estrous cycle differences 329 attenuated following citalopram administration. Compared to our data, these data suggest that 330 species differences may exist in anxiety-like behaviors across the estrous cycle. Although we 331 did not observe an effect of the estrous cycle on behavior within treatment, a previous study 332 observed that C57BL/6J females have less variation in anxiety-like behaviors across the 333 estrous cycle than BALB/cByJ females (Meziane et al., 2007) . Despite this, our data 334 illustrate that FLX treatment has significant effects on behavior relative to vehicle treatment. 335 However, our detailed analyses suggest that these effects of FLX are mainly driven by 336 females in the estrus and diestrus phase. 
